Biogen Idec and Isis Pharmaceuticals have entered into an exclusive, worldwide option and collaboration agreement under which the companies will develop and commercialize an antisense drug for the treatment of myotonic dystrophy type 1 (DM1).   Isis will receive an upfront payment of $12 million and is responsible for the discovery of a lead antisense drug candidate targeting DMPK through Phase II. Isis is eligible to receive as much as $59 million in development milestones prior to licensing. B...